AI assistant
Sending…
Anika Therapeutics, Inc. — Director's Dealing 2021
Jun 17, 2021
33997_dirs_2021-06-17_ae4ea3ac-5946-4f0b-816f-44154d7bdf22.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Anika Therapeutics, Inc. (ANIK)
CIK: 0000898437
Period of Report: 2021-06-15
Reporting Person: Blanchard Cheryl R (Director, President, CEO, Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-15 | Common Stock | M | 2994 | $33.40 | Acquired | 37472 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-15 | Stock Option (Right to Buy) | $33.40 | M | 2994 | Disposed | 2030-04-26 | Common Stock (2994) | Direct |
Footnotes
F1: The stock options vest in three equal annual installments beginning on April 26, 2021.
More from Anika Therapeutics, Inc.
Proxy Solicitation & Information Statement
2026
Jun 1
Interim / Quarterly Report
2026
Apr 30
Major Shareholding Notification
2026
Apr 29
Regulatory Filings
2026
Apr 29
Annual Report
2026
Apr 28
Proxy Solicitation & Information Statement
2026
Apr 28
Proxy Solicitation & Information Statement
2026
Apr 28
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 23
Director's Dealing
2026
Mar 18